<![CDATA[Case Discussion: Selecting BCMA Bispecific Therapy for a Patient With Relapsed/Refractory Multiple Myeloma and Limited Access to CAR-T]]>

Summary

Faculty discussion of treatment options for a relapsed/refractory multiple myeloma patient with four prior lines of therapy who faces barriers to CAR-T treatment due to limited caregiver support and distance from a cellular therapy center. The discussion focuses on selecting BCMA bispecific therapy as an alternative approach.